Ongoing trials

All Multiple Myeloma patients including smoldering Multiple Myeloma

Targovax: A phase 1/2 study to investigate safety, tolerability and efficacy with TG01/QS-21 vaccine administration in patients with confirmed KRAS or NRAS codon 12/13 mutation and high risk smoldering multiple myeloma, or multiple myeloma, and evidence of measurable disease following ≥ 1 line of treatment

Newly Diagnosed Multiple Myeloma

MajesTEC-7: A phase 3 randomized study comparing teclistamab in combination with daratumumab and lenalidomide (Tec-DR) and talquetamab in combination with daratumumab and lenalidomide (Tal-DR) versus daratumumab, lenalidomide, and dexamethasone (DRd) in participants with newly diagnosed multiple myeloma who are either ineligible or not intended for autologous stem cell transplant as initial therapy

Dreamm-10: A Phase 3, randomized, open-label study of Belantamab Mafodotin administered in combination with lenalidomide and dexamethasone (BRd) versus daratumumab, lenalidomide, and dexamethasone (DRd) in participants with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplantation

Relapsed/Refractory Multiple Myeloma

ACT: Phase 1/2 UMBRELLA trial evaluating isatuximab with or without dexamethasone in combination with novel agents in relapsed or refractory multiple myeloma

CA057-003: Phase 1b/2a study to evaluate mezigdomide in combination with other treatments in relapsed or refractory multiple myeloma

Impress: A multi-cohort phase 2 treatment clinical study investigating efficacy of approved drugs outside indication in patients with advanced cancer. Ceritinib is investigated in triple-exposed multiple myeloma patients with high LTK expression

QUINTESSENTIAL-2: A phase 3, randomized study to compare the efficacy and safety of Arlocabtagene Autoleucel (BMS-986393), a GPRC5D-directed CAR-T cell therapy, versus standard regimens in adult participants with relapsed or refractory and lenalidomide-exposed multiple myeloma

MagnetisMM-32: A phase 3, open-label study of elranatamab monotherapy versus elotuzumab, pomalidomide, dexamethasone (EPd) or carfilzomib, dexamethasone (Kd) in participants with relapsed/refractory multiple myeloma who received prior anti-CD38 directed therapy

TRIgnite-1: A Phase 1, open-label study to evaluate the safety and anti-myeloma activity of ISB 2001, a BCMAxCD38xCD3-targeting trispecific antibody, in participants with relapsed/refractory multiple myeloma

M24-555: Phase 1/2 study of Etentamig (a BCMAxCD3-targeting bi-specific antibody) in combination with a CELMoD agent for the treatment of patients with relapsed/refractory multiple myeloma